real-time news and commentary for investors
Friday, Sep 6
Trovagene partners with USC in clinical study of cancer monitoring technology
- TrovaGene (TROV -0.1%) says it's partnering with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using itss cell-free DNA assays.
- The study is designed to demonstrate that cell-free DNA obtained from urine is a viable systemic sample for colorectal cancer disease monitoring, which includes measuring therapy response, identifying cancer genomic changes and monitoring disease progression.